PLYMOUTH MEETING, Pa.,
March 8, 2022 /PRNewswire/
-- INOVIO (NASDAQ:INO), a biotechnology company focused on
developing and commercializing DNA medicines to help protect people
from infectious diseases and help treat people with cancer and
HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will participate
in a fireside chat and 1x1 investor meetings at Oppenheimer's 32nd
Annual Healthcare Conference on Tuesday,
March 15, 2021.
Oppenheimer's 32nd Annual Healthcare
Conference
Date: Tuesday, March 15,
2021
Time: 8:00 AM ET
Presentation Format: Fireside Chat
A webcast of the presentation will be available through the
INOVIO Investor Relations Events page at
https://ir.inovio.com/events-and-presentations/default.aspx. The
presentation time is subject to change.
About INOVIO
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help protect people from
infectious diseases and help treat people with cancer and
HPV-associated diseases. Our DNA medicines are delivered using our
proprietary smart device to produce a robust and tolerable immune
response against targeted pathogens and cancers. INOVIO is
evaluating candidate VGX-3100 in two Phase 3 trials for
precancerous high-grade cervical dysplasia caused by HPV-16 and/or
HPV-18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate
against COVID-19, in a global Phase 3 trial.
Partners and collaborators include Advaccine, ApolloBio
Corporation, AstraZeneca, The Bill & Melinda Gates Foundation,
Coalition for Epidemic Preparedness Innovations, Defense Advanced
Research Projects Agency/Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense/Department
of Defense, HIV Vaccines Trial Network, International Vaccine
Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium,
National Cancer Institute, National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Ology Bioservices,
the Parker Institute for Cancer Immunotherapy, Plumbline Life
Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher
Scientific, University of Pennsylvania,
Walter Reed Army Institute of Research, and The Wistar Institute.
For more information, visit www.inovio.com.
CONTACTS:
Media: Jeff Richardson,
267-440-4211, jeff.richardson@inovio.com
Investors: Ben Matone, 484-362-0076,
ben.matone@inovio.com
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
DNA medicines, our expectations regarding our research and
development programs, including the planned initiation and conduct
of preclinical studies and clinical trials and the availability and
timing of data from those studies and trials, and our ability to
successfully manufacture and produce large quantities of our
product candidates if they receive regulatory approval. Actual
events or results may differ from the expectations set forth herein
as a result of a number of factors, including uncertainties
inherent in pre-clinical studies, clinical trials, product
development programs and commercialization activities and outcomes,
our ability to secure sufficient manufacturing capacity to mass
produce our product candidates, the availability of funding to
support continuing research and studies in an effort to prove
safety and efficacy of electroporation technology as a delivery
mechanism or develop viable DNA medicines, our ability to support
our pipeline of DNA medicine products, the ability of our
collaborators to attain development and commercial milestones for
products we license and product sales that will enable us to
receive future payments and royalties, the adequacy of our capital
resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
us or our collaborators, including alternatives that may be more
efficacious or cost effective than any therapy or treatment that we
and our collaborators hope to develop, issues involving product
liability, issues involving patents and whether they or licenses to
them will provide us with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
we can finance or devote other significant resources that may be
necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of our technology by potential
corporate or other partners or collaborators, capital market
conditions, the impact of government healthcare proposals and other
factors set forth in our Annual Report on Form 10-K for the year
ended December 31, 2021 and other
filings we make from time to time with the Securities and Exchange
Commission. There can be no assurance that any product candidate in
our pipeline will be successfully developed, manufactured or
commercialized, that final results of clinical trials will be
supportive of regulatory approvals required to market products, or
that any of the forward-looking information provided herein will be
proven accurate. Forward-looking statements speak only as of the
date of this release, and we undertake no obligation to update or
revise these statements, except as may be required by law.
View original
content:https://www.prnewswire.com/news-releases/inovio-to-present-at-oppenheimers-32nd-annual-healthcare-conference-301497449.html
SOURCE INOVIO Pharmaceuticals, Inc.